GVHD-derived plasma as a priming strategy of mesenchymal stem cells.
Graft-versus-host disease
Immunomodulation
Lymphocytes
Mesenchymal stem cell priming
Mesenchymal stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
16 04 2020
16 04 2020
Historique:
received:
17
12
2019
accepted:
20
03
2020
revised:
21
02
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovative priming strategy based on the plasma obtained from GVHD patients and tested whether this approach could enhance the immunosuppressive capacity of MSCs. We obtained the plasma from healthy as well as acute (aGVHD) and chronic (cGVHD) GVHD donors. Plasma samples were characterized according to the TNF-α, IFN-γ, IL-10, IL-1β, IL-12p40, and IL-15 cytokine levels. The MSCs primed with such plasmas were investigated according to surface markers, morphology, proliferation, mRNA expression, and the capacity to control T cell proliferation and Treg generation. Interestingly, 57% of aGVHD and 33% of cGVHD plasmas significantly enhanced the immunosuppressive potential of MSCs. The most suppressive MSCs presented altered morphology, and those primed with cGHVD displayed a pronounced overexpression of ICAM-1 on their surface. Furthermore, we observed that the ratio of IFN-γ to IL-10 cytokine levels in the plasma used for MSC priming was significantly correlated with higher suppressive potential and Treg generation induction by primed MSCs, regardless of the clinical status of the donor. This work constitutes an important proof of concept which demonstrates that it is possible to prime MSCs with biological material and also that the cytokine levels in the plasma may affect the MSC immunosuppressive potential, serving as the basis for the development of new therapeutic approaches for the treatment of immune diseases.
Sections du résumé
BACKGROUND
Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovative priming strategy based on the plasma obtained from GVHD patients and tested whether this approach could enhance the immunosuppressive capacity of MSCs.
METHODS
We obtained the plasma from healthy as well as acute (aGVHD) and chronic (cGVHD) GVHD donors. Plasma samples were characterized according to the TNF-α, IFN-γ, IL-10, IL-1β, IL-12p40, and IL-15 cytokine levels. The MSCs primed with such plasmas were investigated according to surface markers, morphology, proliferation, mRNA expression, and the capacity to control T cell proliferation and Treg generation.
RESULTS
Interestingly, 57% of aGVHD and 33% of cGVHD plasmas significantly enhanced the immunosuppressive potential of MSCs. The most suppressive MSCs presented altered morphology, and those primed with cGHVD displayed a pronounced overexpression of ICAM-1 on their surface. Furthermore, we observed that the ratio of IFN-γ to IL-10 cytokine levels in the plasma used for MSC priming was significantly correlated with higher suppressive potential and Treg generation induction by primed MSCs, regardless of the clinical status of the donor.
CONCLUSIONS
This work constitutes an important proof of concept which demonstrates that it is possible to prime MSCs with biological material and also that the cytokine levels in the plasma may affect the MSC immunosuppressive potential, serving as the basis for the development of new therapeutic approaches for the treatment of immune diseases.
Identifiants
pubmed: 32299501
doi: 10.1186/s13287-020-01659-x
pii: 10.1186/s13287-020-01659-x
pmc: PMC7164240
doi:
Substances chimiques
Cytokines
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Références
Nat Rev Clin Oncol. 2014 Sep;11(9):536-47
pubmed: 24958183
Am J Blood Res. 2013 Aug 19;3(3):225-38
pubmed: 23997985
Cytotherapy. 2019 Jan;21(1):17-31
pubmed: 30503100
Stem Cell Res Ther. 2019 Aug 23;10(1):267
pubmed: 31443680
Cell Physiol Biochem. 2018;46(6):2624-2635
pubmed: 29763906
Lancet. 2004 May 1;363(9419):1439-41
pubmed: 15121408
Stem Cells Dev. 2010 Jul;19(7):1075-9
pubmed: 19886821
Biol Blood Marrow Transplant. 2010 Sep;16(9):1293-301
pubmed: 20350611
Cytotherapy. 2016 Jul;18(7):846-59
pubmed: 27260206
Stem Cell Res. 2011 Jul;7(1):66-74
pubmed: 21546330
Cytotherapy. 2009;11(5):570-83
pubmed: 19565371
Clin Exp Immunol. 2009 Apr;156(1):149-60
pubmed: 19210524
Stem Cell Rev Rep. 2014 Jun;10(3):351-75
pubmed: 24510581
Bone Marrow Transplant. 2018 Jul;53(7):852-862
pubmed: 29379171
Stem Cells. 2016 Sep;34(9):2429-42
pubmed: 27299362
Front Immunol. 2012 Aug 02;3:231
pubmed: 22876244
J Immunol. 2014 Feb 15;192(4):1491-501
pubmed: 24403533
Aesthetic Plast Surg. 2012 Oct;36(5):1254-9
pubmed: 22936376
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
Stem Cell Res Ther. 2019 Nov 26;10(1):345
pubmed: 31771622
Stem Cell Res Ther. 2016 Dec 30;7(1):189
pubmed: 28038684
Eur J Immunol. 2013 Oct;43(10):2741-9
pubmed: 23817958
J Immunol. 2015 May 15;194(10):4604-12
pubmed: 25934923
Lancet. 2008 May 10;371(9624):1579-86
pubmed: 18468541
Exp Mol Med. 2009 May 31;41(5):315-24
pubmed: 19307751
Cytokine Growth Factor Rev. 2019 Jun;47:32-42
pubmed: 31129018
J Immunol. 2010 Jul 1;185(1):302-12
pubmed: 20511548
Stem Cell Res Ther. 2019 May 2;10(1):131
pubmed: 31046833
Br J Haematol. 2013 Nov;163(4):501-9
pubmed: 23992039
Transplantation. 1998 Oct 15;66(7):863-71
pubmed: 9798695
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2598-E2607
pubmed: 28283659
Bone Marrow Transplant. 2014 Mar;49(3):324-31
pubmed: 23872737
Biomed Res Int. 2014;2014:216806
pubmed: 25025040
Biol Blood Marrow Transplant. 2012 Apr;18(4):557-64
pubmed: 21820393
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
Stem Cell Res Ther. 2017 Dec 29;8(1):292
pubmed: 29287601
World J Gastroenterol. 2015 Apr 14;21(14):4379-84
pubmed: 25892890
Blood. 2004 Jun 15;103(12):4619-21
pubmed: 15001472
Cells. 2019 Jan 05;8(1):
pubmed: 30621275
Transplantation. 2008 Nov 15;86(9):1283-91
pubmed: 19005411
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):25-32
pubmed: 17869550
Front Immunol. 2013 Sep 04;4:201
pubmed: 24027567